"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Veru's pivot with enobosarm: groundbreaking Phase 2b results enhance GLP-1 therapy outcomes. A positive launch could yield ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...